Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation

Amar U Kishan1, Nicholas Marco2, Melanie-Birte Schulz-Jaavall3

  • 1Department of Radiation Oncology, University of California, Los Angeles, United States; Department of Urology, University of California, Los Angeles, United States.

Abstract

Insights

Single nucleotide polymorphisms (SNPs) disrupting microRNA targets can predict genitourinary toxicity after prostate cancer radiotherapy. These predictive biomarkers are specific to radiation fractionation, highlighting the need for personalized treatment strategies.

Area of Science:

  • Oncology
  • Genetics
  • Radiation Oncology

Background:

  • Radiotherapy for prostate cancer can lead to genitourinary (GU) toxicity.
  • Identifying predictive biomarkers for toxicity is crucial for personalized treatment.

Purpose of the Study:

  • To investigate if single nucleotide polymorphisms (SNPs) that disrupt microRNA targets (mirSNPs) can predict GU toxicity after prostate cancer radiotherapy.
  • To determine if mirSNPs have differential predictive value based on radiation fractionation schedules.

Main Methods:

  • 201 prostate cancer patients treated with conventionally-fractionated radiotherapy (CF-RT) or stereotactic body radiotherapy (SBRT) were analyzed.
  • Germline DNA was assessed for functional mirSNPs.
  • Machine learning models (random forest, boosted trees, elastic net) were developed to predict late grade ≥2 GU toxicity.

Main Results:

  • Crude incidence of late grade ≥2 GU toxicity was 16% for CF-RT and 15% for SBRT.
  • An elastic net model using 22 mirSNPs accurately predicted toxicity risk in CF-RT patients (AUC 0.76-0.81).
  • A distinct model using 32 mirSNPs predicted toxicity risk in SBRT patients (AUC 0.81-0.87).

Conclusions:

  • Germline mirSNPs accurately predict late GU toxicity after prostate cancer radiotherapy.
  • Predictive models are treatment-specific, indicating fractionation-dependent radiation sensitivity.
  • Prospective studies are needed to validate these predictive biomarkers.